Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
This study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug (ruxolitinib) can improve outcomes of patients with CMML.
Chronic Myelomonocytic Leukemia|Leukemia
DRUG: Ruxolitinib
Overall Response, Number of participants achieving clinical benefit defined as hematologic improvement, complete remission, partial remission, or stable disease by the International Working Group Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Criteria., At week 16
Time to Acute Myeloid Leukemia (AML) Transformation, Time to AML transformation according to World Health Organization (WHO) Critieria, Every 6 months after conclusion of treatment until end of study (40.3 months)|Overall Survival, Overall survival will be from first dose of study drug until failure or death from any cause., Up to 2 years|Duration of Response, Duration of response measured using time to AML transformation according to WHO Critieria, Up to 2 years
This study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug (ruxolitinib) can improve outcomes of patients with CMML.